AquaBounty Technologies, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03842K3095
USD
1.02
0.06 (5.82%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About AquaBounty Technologies, Inc. stock-summary
stock-summary
AquaBounty Technologies, Inc.
Pharmaceuticals & Biotechnology
AquaBounty Technologies, Inc. is a engaged in research, development and commercialization of the commercial viability of a group of proteins, antifreeze proteins (AFPs). The Company focuses on the managing aquaculture productivity. It offers AquAdvantage Salmon (AAS), which can be grown in contained, land-based facilities. It offers AquAdvantage Salmon for land-based facilities that can be built closer to consumers to manage the need for air freight shipping and transportation. The Company's subsidiaries include AquaBounty Canada, Inc., which operates a commercial biotechnology laboratory that conducts research and development programs related to the Company's technologies; AquaBounty Panama, S. de R.L.; AquaBounty Farms, Inc.; AquaBounty Farms Indiana LLC, and AquaBounty Brasil Participacoes Ltda., which conducts commercial trials of the Company's AquAdvantage Salmon.
Company Coordinates stock-summary
Company Details
2 Clock Tower Pl Ste 395 , MAYNARD MA : 01754-2539
stock-summary
Tel: 1 978 6486000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (3.28%)

Foreign Institutions

Held by 8 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Richard Clothier
Non-Executive Independent Chairman
Ms. Sylvia Wulf
President, Chief Executive Officer, Executive Director
Mr. Rick Sterling
Non-Executive Director
Mr. Richard Huber
Non-Executive Independent Director
Ms. Christine St.Clare
Non-Executive Independent Director
Mr. James Turk
Non-Executive Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.57

stock-summary
Return on Equity

-93.37%

stock-summary
Price to Book

0.36